Other News

American College of Cardiology Acquires MedAxiom

WASHINGTON, Feb. 4, 2019 /PRNewswire/ — The American College of Cardiology Foundation has acquired MedAxiom, a cardiovascular membership, services and consulting firm, adding the company’s recognized leadership in cardiovascular operations, performance improvement, and business acumen to ACC’s world class science, education, registry, quality improvement and advocacy work. Through this acquisition, the ACC will expand […]

Teleflex Announces U.S. FDA Premarket Approval of MANTA™ Vascular Closure Device

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced that it received premarket approval (PMA) from the U.S. Food and Drug Administration for the MANTA™ Vascular Closure Device – the first commercially available biomechanical vascular closure device designed specifically […]

BD Announces Results for 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

FRANKLIN LAKES, N.J., Feb. 5, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31, 2018.  This represents an increase of 35.1 percent from the prior-year period, which is primarily due to the acquisition of […]

AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern […]

Cook Medical Receives U.S. FDA Approval for Aortic Dissection Device

BLOOMINGTON, Ind.–(BUSINESS WIRE)–Today, Cook Medical announced its recent approval from the U.S. FDA for its Zenith Dissection Endovascular System. The system, consisting of a proximal stent-graft component and a distal bare stent component, provides physicians a less invasive alternative to open surgery for repair of Type B dissections of the […]

First Atrial Fibrillation Patient Treated In Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter

IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study** which evaluates the company’s QDOT MICRO Radiofrequency […]

CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease

TARRYTOWN, N.Y. and PARIS, Feb. 4, 2019 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent® (alirocumab) Injection, recommending a new indication to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels as an […]

Ascyrus Medical Announces CE Mark Approval for the Ascyrus Medical Dissection Stent (AMDS)

BOCA RATON, FLA. (PRWEB) FEBRUARY 01, 2019 With approval, the AMDS offers physicians and patients in Europe the first marketed arch remodeling device and a breakthrough treatment for type A aortic dissections. Ascyrus Medical, a privately-owned medical device company focused on innovative treatments for aortic dissections, today announced the CE mark […]

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

BASEL, Switzerland and DURHAM, N.C., Jan. 31, 2019 /PRNewswire/ — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, will present its latest nonclinical and clinical data at the Pulmonary Vascular Research Institute (PVRI) 13th Annual World Congress on Pulmonary Vascular Disease, […]